window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 16, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Latent Labs

  • Digital & Data,Drug Discovery & Development,Research & Development

    Latent Labs opens lab-validated AI drug design platform to researchers worldwide

    Latent Labs has launched its artificial intelligence-powered drug design platform [...]

    July 15, 2026
  • Advanced Therapies,Digital & Data,Drug Discovery & Development

    Latent Labs unveils AI model Latent-X for instant, lab-validated protein binder design

    No-code platform opens early access to generative binder design with [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Sofinnova Partners and NVIDIA join forces to boost European AI in life sciences

    Sofinnova Partners has announced a new collaboration with NVIDIA to [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Nucleome strengthens 3D genomics platform with US patent for Micro Capture-C technology
    Categories: Drug Discovery & Development, Genomics and sequencing, Research & Development
  • Novogene expands Cambridge Omics Centre with untargeted metabolomics service
    Categories: Drug Discovery & Development, Genomics and sequencing, Research & Development
  • ProMIS reports first human evidence of PMN310 target engagement in Alzheimer’s disease
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top